DK1696909T3 - Benzothiazolderivater til behandling af diabetes - Google Patents

Benzothiazolderivater til behandling af diabetes

Info

Publication number
DK1696909T3
DK1696909T3 DK04787110T DK04787110T DK1696909T3 DK 1696909 T3 DK1696909 T3 DK 1696909T3 DK 04787110 T DK04787110 T DK 04787110T DK 04787110 T DK04787110 T DK 04787110T DK 1696909 T3 DK1696909 T3 DK 1696909T3
Authority
DK
Denmark
Prior art keywords
unsubstituted
substituted
treatment
benzothiazole derivatives
group
Prior art date
Application number
DK04787110T
Other languages
Danish (da)
English (en)
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of DK1696909T3 publication Critical patent/DK1696909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK04787110T 2003-09-12 2004-09-08 Benzothiazolderivater til behandling af diabetes DK1696909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
DK1696909T3 true DK1696909T3 (da) 2008-01-02

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04787110T DK1696909T3 (da) 2003-09-12 2004-09-08 Benzothiazolderivater til behandling af diabetes

Country Status (18)

Country Link
US (2) US20070088017A1 (el)
EP (1) EP1696909B1 (el)
JP (1) JP5021307B2 (el)
AT (1) ATE378047T1 (el)
AU (1) AU2004271740B2 (el)
CA (1) CA2534314C (el)
CY (1) CY1107820T1 (el)
DE (1) DE602004010178T2 (el)
DK (1) DK1696909T3 (el)
ES (1) ES2297494T3 (el)
HK (1) HK1096594A1 (el)
HR (1) HRP20070527T3 (el)
IL (1) IL174250A (el)
NO (1) NO20061600L (el)
PL (1) PL1696909T3 (el)
PT (1) PT1696909E (el)
SI (1) SI1696909T1 (el)
WO (1) WO2005025567A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2137173A2 (en) * 2007-04-17 2009-12-30 Laboratoires Serono SA Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9604916B2 (en) 2012-07-13 2017-03-28 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1450792B1 (en) * 2001-12-07 2006-09-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives for the treatment of scleroderma
RS51407B (en) * 2002-04-25 2011-02-28 Laboratoires Serono Sa PIPERAZINE BENZOTIASOLS AS AGENTS FOR TREATMENT OF CERABRAL ISCHEMICAL OR CNS DISORDERS

Also Published As

Publication number Publication date
SI1696909T1 (sl) 2008-02-29
CA2534314A1 (en) 2005-03-24
WO2005025567A1 (en) 2005-03-24
PL1696909T3 (pl) 2008-04-30
JP2007505083A (ja) 2007-03-08
ES2297494T3 (es) 2008-05-01
ATE378047T1 (de) 2007-11-15
IL174250A (en) 2011-01-31
AU2004271740B2 (en) 2010-10-28
IL174250A0 (en) 2006-08-01
AU2004271740A1 (en) 2005-03-24
HRP20070527T3 (en) 2007-12-31
DE602004010178D1 (de) 2007-12-27
US20070088017A1 (en) 2007-04-19
NO20061600L (no) 2006-04-07
HK1096594A1 (en) 2007-06-08
US20140107116A1 (en) 2014-04-17
JP5021307B2 (ja) 2012-09-05
CA2534314C (en) 2012-11-13
CY1107820T1 (el) 2013-06-19
EP1696909B1 (en) 2007-11-14
DE602004010178T2 (de) 2008-09-11
EP1696909A1 (en) 2006-09-06
PT1696909E (pt) 2007-12-21

Similar Documents

Publication Publication Date Title
NO20061600L (no) Bensotiazol-derivater for behandling av diabetes
NO20061614L (no) Benzimidazolacetonitriler
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
NO20083026L (no) Terapeutisk middel for diabetes
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
EA200601869A1 (ru) Карбоновые кислоты
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
CY1112466T1 (el) ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
ATE551997T1 (de) Sulfonamid-derivate zur behandlung von diabetes
WO2010045303A3 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
ATE476422T1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
CO6331470A2 (es) Antogonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
NO20061599L (no) Benzoksazol acetonitriler
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
ATE455772T1 (de) Alkinylarylcarbonsäureamide
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
GT200300194A (es) Derivados de indolilo
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
DK1656139T3 (da) Aryldicarboxamider